Open AccessAntibiotic Therapy and Gastrointestinal Graft-Versus-Host Disease in the Allogeneic Stem Cell Transplantation Population
Author(s) -
MSN Jessica Thomas,
MSN Christi Bowe,
Joyce E. Dains
Publication year - 2022
Publication title -
journal of the advanced practitioner in oncology
Language(s) - English
Resource type - Journals
eISSN - 2150-0886
pISSN - 2150-0878
DOI - 10.6004/jadpro.2022.13.1.5
Subject(s) - medicine , hematopoietic stem cell transplantation , transplantation , graft versus host disease , population , antibiotics , intensive care medicine , disease , stem cell , environmental health , microbiology and biotechnology , biology , genetics
Hematopoietic stem cell transplantation patients undergo rigorous courses of myeloablative chemotherapy that increase vulnerability for infections. Complications can arise in the form of graft-vs.-host disease (GvHD) manifesting in various organs, including the skin, lung, liver, and gastrointestinal (GI) tract. Antibiotic therapy is generally begun in order to prevent further complications from infection but may increase the risk for acute GI GvHD. Studies that investigated antibiotic therapy and the subsequent occurrence of GI GvHD in allogeneic stem cell transplantation (aSCT) patients were reviewed.